DUBLIN, Calif., March 2 /PRNewswire-FirstCall/ -- SuperGen Inc. today announced it will present information on its CLIMB(TM) drug discovery technology and an overview of its current development pipeline at an analyst and investor event today in Salt Lake City. The presentations will begin at noon EST at the company’s research and development facility.
As part of the event, SuperGen will provide a comprehensive overview of CLIMB(TM), which combines novel in vitro and in vivo processes with bioinformatics capabilities to create an efficient and effective system to identify and develop drug candidates.
In addition, SuperGen will present an update on two of its late-stage pre- clinical products: MP470 and MP529. MP470 is a tyrosine kinase inhibitor that is active against a broad spectrum of human cancer cell lines and tumor models. Information will include activity data against a number of targets, including the RAD51 protein, which is an important protein responsible for repairing double strand DNA breaks that can occur following some traditional chemotherapy treatments. Furthermore, the presentation will include information about MP529, the company’s second kinase inhibitor in the oncology area specifically targeted toward aurora-A kinase (without affecting aurora-B proteins).
SuperGen will also present information about several new programs, including a new cancer target, Pim-1, and its potential inhibitor, as well as a tyrosine kinase target, JAK2, and its potential inhibitor, which has potent anti-myeloproliferative and leukemic activity.
Finally, the company will detail its current CLIMB(TM) discovery efforts, including its programs focused on DNA methyltransferase inhibition, which demonstrate the power and efficiency of the discovery platform.
The presentations will be Webcast by CCBN and are accessible in the investor relations section of SuperGen’s Web site at www.supergen.com. A replay will be available in the same location for 90 days following the event.
About SuperGen
Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company’s results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company’s filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts: SuperGen Timothy L. Enns S.V.P., Corporate Communications& Business Development (925) 560-0100 x111 tenns@supergen.com Noonan Russo Greg Geissman Director of Media Relations (858) 646-3058 greg.geissman@eurorscg.com
SuperGen Inc.
CONTACT: Timothy L. Enns, SuperGen,S.V.P., Corporate Communications&Business Development, +1-925-560-0100 ext.111, tenns@supergen.com; or GregGeissman, Noonan Russo, Director of Media Relations, +1-858-646-3058,greg.geissman@eurorscg.com
Web site: http://www.supergen.com/
